missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Durvalumab Recombinant Monoclonal Antibody
Recombinant Monoclonal Antibody
Marke: Invitrogen™ MA558380
Dieser Artikel kann nicht zurückgegeben werden.
Rückgaberichtlinie anzeigen
Beschreibung
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Durvalumab with trade name Imfinzi, is an FDA-approved anti-cancer drug. It is known as a checkpoint inhibitor drug, developed by Medimmune/AstraZeneca. Durvalumab is a human IgG1 kappa monoclonal antibody. It blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).
Spezifikation
| Durvalumab | |
| Recombinant Monoclonal | |
| Unconjugated | |
| Imfinzi; MEDI4736 | |
| Protein A | |
| RUO | |
| Human | |
| Antibody | |
| IgG1 κ |
| ELISA, Flow Cytometry | |
| 1 mg/mL | |
| 25mM histidine with 0.01% Tween 80, 8% sucrose and no preservative; pH 6.2 | |
| Human | |
| 1 mg | |
| Primary | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Lyophilized |
Berichtigung von Produktinhalten
Bitte geben Sie uns Ihr Feedback zu den Produktinhalten, indem Sie das folgende Formular ausfüllen.
Name des Produkts
Haben Sie Verbesserungsvorschläge?Übermitteln Sie eine inhaltliche Korrektur